Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19280031 | IMMUNO-THERAPEUTIC CHEMICAL COMPOSITIONS AND USES THEREOF | July 2025 | December 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19192108 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | April 2025 | January 2026 | Allow | 9 | 1 | 0 | No | No |
| 19172172 | PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR | April 2025 | September 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 19081876 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | March 2025 | December 2025 | Allow | 9 | 1 | 0 | No | No |
| 19060522 | Piperidine Urea Derivatives for Use as Inotropic Agents | February 2025 | November 2025 | Allow | 9 | 2 | 0 | No | No |
| 18653610 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | May 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18653655 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | May 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18628366 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | April 2024 | March 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18628353 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | April 2024 | March 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18627708 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18613270 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE | March 2024 | June 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18584914 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18383517 | GOLD COMPLEXES AS ANTICANCER AGENT | October 2023 | November 2025 | Allow | 25 | 0 | 0 | No | No |
| 18486623 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | October 2023 | December 2024 | Allow | 14 | 2 | 0 | No | No |
| 18244500 | METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS | September 2023 | May 2024 | Allow | 8 | 1 | 0 | No | No |
| 18220708 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | July 2023 | December 2023 | Allow | 5 | 0 | 0 | No | No |
| 18213985 | INTESTINE-SPECIFIC PARTIAL AGONISTS OF FARNESOID X RECEPTOR AND USES THEREOF | June 2023 | October 2025 | Allow | 28 | 0 | 0 | No | No |
| 18340005 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | June 2023 | March 2024 | Allow | 9 | 1 | 0 | No | No |
| 18333162 | Inhibitors of Lysyl Oxidases | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18321159 | USING GENO- OR PHENOTYPING TO ADJUST LSD DOSING | May 2023 | May 2025 | Abandon | 24 | 4 | 0 | Yes | No |
| 18295097 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2023 | November 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18295146 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2023 | March 2024 | Allow | 11 | 1 | 0 | No | No |
| 18295138 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2023 | February 2024 | Allow | 10 | 1 | 0 | No | No |
| 18295114 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | April 2023 | November 2023 | Allow | 7 | 1 | 0 | No | No |
| 18194761 | LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS | April 2023 | May 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18194498 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18194503 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18194496 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | March 2023 | November 2023 | Allow | 7 | 1 | 0 | No | No |
| 18194491 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18117978 | SPIROCYCLIC COMPOUNDS | March 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18161633 | BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS | January 2023 | January 2024 | Allow | 12 | 2 | 0 | No | No |
| 18015254 | Lipidoids for Nucleic Acid Transfection and Use Thereof | January 2023 | October 2025 | Allow | 33 | 0 | 0 | No | No |
| 18011084 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | December 2022 | May 2023 | Allow | 5 | 0 | 0 | No | No |
| 18081603 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | December 2022 | September 2024 | Allow | 22 | 3 | 0 | No | No |
| 18077096 | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS | December 2022 | August 2025 | Abandon | 32 | 5 | 0 | Yes | No |
| 18047188 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | October 2022 | September 2024 | Allow | 23 | 2 | 0 | No | Yes |
| 17938256 | METHODS FOR INHIBITING THE PROGRESSION OF NEURODEGENERATIVE DISEASES | October 2022 | March 2026 | Allow | 41 | 1 | 1 | No | No |
| 17949713 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17902684 | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs | September 2022 | March 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17893918 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | August 2022 | February 2026 | Allow | 41 | 1 | 0 | No | No |
| 17892982 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | August 2022 | December 2022 | Allow | 4 | 1 | 0 | No | No |
| 17891991 | CCL5 Inhibitors | August 2022 | February 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 17877538 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | July 2022 | August 2023 | Allow | 12 | 1 | 1 | No | No |
| 17869896 | USING GENO- OR PHENOTYPING TO ADJUST LSD DOSING | July 2022 | March 2025 | Abandon | 31 | 2 | 0 | No | No |
| 17854818 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | June 2022 | September 2025 | Allow | 38 | 1 | 0 | No | No |
| 17842425 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | June 2022 | January 2026 | Allow | 43 | 1 | 0 | No | No |
| 17842389 | TREATMENT OF HCM WITH PYRIMIDINEDIONE COMPOUNDS | June 2022 | March 2024 | Abandon | 21 | 3 | 0 | Yes | No |
| 17831044 | METHODS OF TREATING NASH | June 2022 | October 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17830458 | COMPOSITIONS AND METHODS FOR TREATING RETINOPATHY | June 2022 | March 2025 | Allow | 34 | 0 | 0 | No | No |
| 17749748 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | May 2022 | February 2023 | Abandon | 9 | 1 | 0 | No | No |
| 17738172 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH2 MEDIATED DISEASES | May 2022 | February 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17774489 | ACC INHIBITOR AND USE THEREOF | May 2022 | March 2025 | Allow | 35 | 0 | 0 | No | No |
| 17774684 | MITOCHONDRIA-TARGETING ANTIOXIDANTS | May 2022 | December 2025 | Allow | 44 | 1 | 0 | No | No |
| 17734581 | USE OF ZINC PORPHYRIN AS AN ANTIMICROBIAL | May 2022 | January 2024 | Allow | 20 | 1 | 0 | No | No |
| 17712724 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION USING ANTIVIRAL COCKTAILS | April 2022 | December 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17701391 | PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA | March 2022 | July 2025 | Allow | 40 | 1 | 0 | No | No |
| 17696723 | Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury | March 2022 | March 2024 | Allow | 24 | 4 | 1 | Yes | No |
| 17695259 | Bi-functional Molecules to Degrade Circulating Proteins | March 2022 | November 2025 | Allow | 44 | 1 | 0 | No | No |
| 17693371 | NOVEL INHIBITORS OF LYSYL OXIDASES | March 2022 | March 2023 | Allow | 12 | 0 | 0 | No | No |
| 17684279 | SYNERGISTIC COMBINATION THERAPY FOR TREATING ALS | March 2022 | February 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17634184 | TOPICAL COMPOSITION COMPRISING A PROSTAGLANDIN ANALOGUE | February 2022 | October 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17591798 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | March 2025 | Abandon | 37 | 5 | 0 | No | No |
| 17591808 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | March 2025 | Abandon | 37 | 5 | 0 | No | No |
| 17591727 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | August 2025 | Abandon | 42 | 5 | 0 | Yes | No |
| 17591724 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | February 2025 | Abandon | 36 | 4 | 0 | No | No |
| 17591813 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | March 2025 | Abandon | 38 | 5 | 0 | No | No |
| 17591783 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | September 2025 | Abandon | 43 | 5 | 0 | No | No |
| 17591777 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | February 2022 | March 2025 | Abandon | 37 | 5 | 0 | No | No |
| 17631348 | OXAZEPINONE DERIVATIVE, AGRICULTURAL/HORTICULTURAL INSECTICIDE CONTAINING THE SAME, AND METHOD FOR USING THE SAME | January 2022 | April 2025 | Allow | 38 | 1 | 0 | No | No |
| 17628904 | ORAL GSNOR INHIBITOR AND PHARMACEUTICAL USE THEREOF | January 2022 | March 2023 | Allow | 14 | 1 | 0 | No | No |
| 17580429 | CCL5 Inhibitors | January 2022 | May 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17551843 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | December 2021 | September 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17547819 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | December 2021 | August 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17537663 | ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE | November 2021 | August 2022 | Abandon | 9 | 1 | 0 | No | No |
| 17535692 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | November 2021 | September 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17517796 | METHOD FOR TREATING HYPERTENSION BY USING COMPOUND | November 2021 | December 2023 | Allow | 26 | 1 | 0 | No | No |
| 17516591 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF | November 2021 | August 2025 | Allow | 46 | 1 | 0 | No | No |
| 17507037 | ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE | October 2021 | August 2025 | Allow | 46 | 1 | 0 | No | No |
| 17506836 | Methods and Compositions for Inhibition of Polymerase | October 2021 | August 2025 | Allow | 46 | 1 | 0 | No | No |
| 17451601 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | October 2021 | August 2025 | Allow | 46 | 1 | 0 | No | No |
| 17492427 | SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER | October 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17486695 | GERM CELL NUCLEAR FACTOR LIGANDS AND METHODS OF USE THEREOF | September 2021 | June 2025 | Allow | 45 | 2 | 1 | No | No |
| 17486721 | TREPROSTINIL ADMINISTRATION BY INHALATION | September 2021 | April 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17479121 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | September 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17474203 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL[-BENZAMIDE | September 2021 | December 2024 | Allow | 39 | 2 | 0 | No | No |
| 17447397 | SOLID DISPERSION FORMULATIONS OF AN FXR AGONIST | September 2021 | May 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17471858 | ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17459117 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | August 2021 | January 2025 | Allow | 41 | 1 | 0 | No | No |
| 17411341 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | August 2021 | January 2023 | Allow | 16 | 0 | 0 | No | No |
| 17408285 | METHODS FOR INHIBITING THE PROGRESSION OF NEURODEGENERATIVE DISEASES | August 2021 | June 2022 | Allow | 10 | 1 | 1 | No | No |
| 17406689 | PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA | August 2021 | January 2022 | Allow | 5 | 0 | 0 | No | No |
| 17403577 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | August 2021 | December 2024 | Allow | 40 | 0 | 0 | No | No |
| 17391909 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | August 2021 | March 2022 | Allow | 7 | 1 | 0 | No | No |
| 17391869 | COMBINATION THERAPIES | August 2021 | November 2023 | Allow | 28 | 1 | 0 | No | No |
| 17388551 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | July 2021 | February 2026 | Abandon | 54 | 2 | 0 | No | No |
| 17380219 | METHODS AND COMPOSITIONS FOR DETECTING PANCREATIC CANCER | July 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17376996 | METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS | July 2021 | October 2023 | Allow | 27 | 1 | 0 | No | No |
| 17373834 | GSNO REDUCTASE INHIBITOR AS AN ADJUNCT THERAPY WITH REMOTE ISCHEMIC CONDITIONING AND THROMBOLYTIC REPERFUSION THERAPIES IN STROKE | July 2021 | December 2021 | Allow | 5 | 1 | 0 | No | No |
| 17372125 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | July 2021 | January 2022 | Allow | 6 | 1 | 0 | No | No |
| 17369203 | Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease | July 2021 | October 2024 | Allow | 40 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHMITT, MICHAEL J.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SCHMITT, MICHAEL J works in Art Unit 1629 and has examined 688 patent applications in our dataset. With an allowance rate of 59.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner SCHMITT, MICHAEL J's allowance rate of 59.9% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SCHMITT, MICHAEL J receive 1.78 office actions before reaching final disposition. This places the examiner in the 39% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SCHMITT, MICHAEL J is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +22.5% benefit to allowance rate for applications examined by SCHMITT, MICHAEL J. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 20.4% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 26.8% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 90.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 88.5% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 60.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 43.9% are granted (fully or in part). This grant rate is in the 36% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.